SS-31 vs Vesilute
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Elamipretide, Bendavia
A mitochondria-targeted peptide that improves cellular energy production. FDA approved for Barth syndrome (September 2025) as FORZINITY, the first approved mitochondria-targeted therapeutic.
Also: ED Dipeptide, Glu-Asp
A synthetic dipeptide (Glu-Asp) bioregulator from the Khavinson peptide family, studied for urinary tract and prostate support. Research suggests it may help with bladder function and prostate microcirculation. Part of the tissue-specific bioregulatory compounds developed over 40+ years of research.
Key Comparison Insights
- SS-31 is FDA approved, while Vesilute remains in research stages.
- Both peptides belong to the Anti-Aging category, suggesting similar primary applications.
- SS-31 has stronger research evidence (FDA Approved) compared to Vesilute (Preclinical).
Detailed Comparison
| Attribute | SS-31 | Vesilute |
|---|---|---|
| Category | Anti-Aging | Anti-Aging |
| FDA Status | FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | SS-31 concentrates 1000-fold in mitochondria, binding to cardiolipin on the inner membrane. It optimizes electron transport chain function, reduces reactive oxygen species, and prevents cardiolipin peroxidation during cellular stress. | Vesilute is a dipeptide bioregulator that targets urogenital tissue. It is believed to normalize cellular function by reducing peptide deficiency and restoring protein synthesis inside cells. Research suggests it may enhance microcirculation within the prostate and support bladder function through epigenetic regulation of gene expression. |
| Common Dosing | 40 mg subcutaneous daily Once daily | 1-2 capsules (10-20 mg) daily 1-2x daily, before meals |
| Administration | Subcutaneous injection or IV infusion | Oral capsules |
| Typical Duration | Variable by condition | 30-day courses, repeat after 4-6 months |
| Best Time to Take | Morning | Morning, before meals |
Possible Side Effects May vary by individual |
|
|
| Research Summary | FDA approved for Barth syndrome in September 2025 under accelerated approval. Ongoing trials for dry age-related macular degeneration and primary mitochondrial myopathy. Studies show improved cardiac function, exercise capacity, and mitochondrial efficiency. | Part of Professor Khavinson's bioregulator research at the Saint Petersburg Institute of Bioregulation and Gerontology. Studies investigate potential role in supporting urinary tract and prostate health. Research suggests it may alleviate symptoms linked to bladder dysfunction and reduce prostate issues by improving local circulation. Limited published peer-reviewed data compared to other Khavinson peptides. |
Frequently Asked Questions: SS-31 vs Vesilute
What is the difference between SS-31 and Vesilute?
SS-31 is a anti-aging peptide that a mitochondria-targeted peptide that improves cellular energy production. fda approved for barth syndrome (september 2025) as forzinity, the first approved mitochondria-targeted therapeutic. Vesilute is a anti-aging peptide that a synthetic dipeptide (glu-asp) bioregulator from the khavinson peptide family, studied for urinary tract and prostate support. research suggests it may help with bladder function and prostate microcirculation. part of the tissue-specific bioregulatory compounds developed over 40+ years of research. The main differences lie in their mechanisms of action and clinical applications.
Which is better, SS-31 or Vesilute?
Neither is universally "better" - the choice depends on your specific goals. SS-31 is typically used for anti-aging purposes, while Vesilute is used for anti-aging. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can SS-31 and Vesilute be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using SS-31 and Vesilute together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.
Related Comparisons
View Full Peptide Profiles
Educational Information Only
This comparison of SS-31 and Vesilute is for educational purposes only. Neither this comparison nor any information on this site constitutes medical advice. Always consult with qualified healthcare providers before making decisions about peptides or other substances.